基于风险分层的丙型肝炎治愈后肝细胞癌监测策略的研究进展

摘要/Abstract

摘要： 丙型肝炎是肝细胞癌(HCC)发生的主要病因之一,直接抗病毒药物(DAAs)的出现极大改善了丙型肝炎病毒(HCV)感染患者的临床预后,尽管绝大部分患者经过短期、耐受性良好的口服DAAs治疗后实现了持续病毒学应答(SVR),但HCV治愈后仍存在HCC发生的风险。目前对于HCV相关肝硬化且获得SVR的患者,不论个体情况均建议继续HCC监测,不符合现代个体化医疗的理念。因此,需要更好地筛选出HCV治愈后HCC发生的高风险人群并对其进行长期监测。本文综述了HCV治愈后的临床现状、现有HCC监测方法存在的问题,并重点探讨了基于风险分层的HCV治愈后HCC监测策略的研究进展,旨在为临床诊治及疾病预后提供一定参考。

关键词: 丙型肝炎, 持续病毒学应答, 肝细胞癌, 风险分层

刘佳程, 饶慧瑛. 基于风险分层的丙型肝炎治愈后肝细胞癌监测策略的研究进展[J]. 肝脏, 2025, 30(4): 417-420.

/ 推荐

参考文献

[1] Zheng J, Wang S, Xia L, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances[J]. Signal Transduct Target Ther, 2025,10(1):35.
[2] World Health Organization. Hepatitis C[EB/OL]. (2024)[2024-04-09]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
[3] Ioannou G N, Feld J J. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?[J]. Gastroenterology, 2019,156(2):446-460.e2.
[4] van der Meer A J, Sonneveld M J. Towards risk-based surveillance for HCC after HCV cure?[J]. Hepatology, 2025,81(2):405-407.
[5] Morgan R L, Baack B, Smith B D, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies[J]. Ann Intern Med, 2013,158(5 Pt 1):329-337.
[6] Lockart I, Yeo M G H, Hajarizadeh B, et al. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis[J]. Hepatology, 2022,76(1):139-154.
[7] Krassenburg L A P, Zanjir W R, Georgie F, et al. Evaluation of sustained virologic response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection[J]. Clin Infect Dis, 2021,72(5):780-786.
[8] Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression[J]. J Hepatol, 2017,67(6):1204-1212.
[9] Liu H, Yang X L, Dong Z R, et al. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022,37(9):1654-1665.
[10] Lee S W, Yang S S, Tsai P C, et al. Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study[J]. Clin Mol Hepatol, 2025. (Epub ahead of print)
[11] Singal A G, Rich N E, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma[J]. Gastroenterology, 2019,157(5):1253-1263.e2.
[12] Petrasek J, Singal A G, Rich N E. Harms of hepatocellular carcinoma surveillance[J]. Curr Hepatol Rep, 2019,18(4):383-389.
[13] Kao S Z, Sangha K, Fujiwara N, et al. Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis[J]. EClinicalMedicine, 2024,75:102755.
[14] Chhatwal J, Hajjar A, Mueller P P, et al. Hepatocellular carcinoma incidence threshold for surveillance in virologically cured hepatitis C individuals[J]. Clin Gastroenterol Hepatol, 2024,22(1):91-101.e6.
[15] Konerman M A, Verma A, Zhao B, et al. Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program[J]. Liver Transpl, 2019,25(3):369-379.
[16] van der Meer A J, Feld J J, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication[J]. J Hepatol, 2017,66(3):485-493.
[17] Espina Cadena S, Casas Deza D, Julián Gomara B, et al. Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication[J]. Rev Esp Enferm Dig, 2024,116(6):305-311.
[18] Ioannou G N, Beste L A, Green P K, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores[J]. Gastroenterology, 2019,157(5):1264-1278.e4.
[19] Tahata Y, Sakamori R, Yamada R, et al. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis[J]. Hepatol Res, 2022,52(10):824-832.
[20] Kondili L A, Quaranta M G, Cavalletto L, et al. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort[J]. Dig Liver Dis, 2023,55(7):907-917.
[21] Semmler G, Alonso López S, Pons M, et al. Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure[J]. Hepatology, 2025,81(2):609-624.
[22] Caviglia GP, Fariselli P, D'Ambrosio R, et al. Development and validation of a PIVKA-Ⅱ-based model for HCC risk stratification in patients with HCV-related cirrhosis successfully treated with DAA[J]. Aliment Pharmacol Ther, 2025,61(3):538-549.
[23] Matsumae T, Kodama T, Tahata Y, et al. Thrombospondin-2 as a predictive biomarker for hepatocellular carcinoma after hepatitis C virus elimination by direct-acting antiviral[J]. Cancers, 2023,15(2):357.
[24] Liu C H, Cheng P N, Fang Y J, et al. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection[J]. J Hepatol, 2024. (Epub ahead of print)